Avastin-Injections in Age Related Macular Degeneration:Prospective Study for Optimal Frequency and Follow-up Determinatio
Phase 1
Active, not recruiting
- Conditions
- Age-Related Macular Degeneration (ARMD)MedDRA version: 9.1Level: LLTClassification code 10064930Term: Age-related macular degeneration
- Registration Number
- EUCTR2007-003766-17-NL
- Lead Sponsor
- The Eye Hospital Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 311
Inclusion Criteria
- Informed consent
- Endophthalmitis risks have been made clear
- No preference to paritcipate in the Infliximab for ARMD trial
- Age = 65 years
- Exudative subfoveolar age related macular degeneration
- No significant other ocular disorders affecting visual acuity
- Not immunocompromised
- No allergy for fluorescein or ICG dye injections
- No treatment for ARMD or other retinal problem in the 3 months prior to trial start
- No planned ocular surgery in the first year after trial start
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
None.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method